

## **Dosulepin De-prescribing Guidance**

Dosulepin, a tricyclic antidepressant, is licensed for the treatment of depression, particularly where sedation is required. Although often prescribed to aid sleep, it disrupts REM sleep and there is no evidence that it has sleep-promoting effects. In December 2007 the MHRA advised that, as dosulepin has a narrow safety margin, it should be avoided<sup>1</sup> - it is marked in the BNF as "less suitable for prescribing". NHS England has issued guidance that dosulepin should not routinely be prescribed in primary care<sup>2</sup>. NICE<sup>3</sup> and TEWV FT recommend that it is **not** used. Nevertheless, £3.4 million is still spent on dosulepin every year in the UK<sup>4</sup>.

Dosulepin overdose is associated with a high mortality rate, even with hospital treatment, with cases of ten x 75 mg tablets (750 mg) having fatal consequences.

## Reducing risks with dosulepin

# •Check: • Dose - is it a therapeutic dose? • Indication - is it being used to treat depression? • Effectiveness of treatment • Suicide risk Review • Co-prescribing of interacting drugs known to increase cardio-toxicity Comorbidity • Risks/benefits of dosulepin • NICE does not recommend use of dosulepin · Alternative options e.g. stopping, switching (see handy comparison **Discuss** chart via link below) Document outcome of discussions · Clearly identify reason if continuing dosulepin • Document treatment plan if stopping Document or switching

#### Licensed dose:

75 - 225 mg daily in divided doses or at bedtime Elderly: 50 mg daily initially

### **HIGHLY toxic in overdose**

Less than 1 weeks' supply likely to cause serious toxicity or death. Never prescribe if a risk of

suicide identified

#### Interacting medicines:

- ACE inhibitors, alcohol, alpha blockers, angiotensin II blockers, atypical antipsychotics, beta-blockers, calcium channel blockers, L-dopa, nitrates -Hypotension
- Carbamazepine, NSAIDs, SSRIs Hyponatraemia
- Typical antipsychotics Hypotension & antimuscarinic effects
- Diuretics Hyponatraemia & hypotension
- Lithium Neurotoxicity
- MAOIs, tranylcypromine Increased toxicity
- TCAs Hyponatraemia, hypotension & antimuscarinic effects

Dosulepin should be avoided in patients with cardiac disease, diabetes, epilepsy, hepatic impairment, renal impairment, Parkinson's disease and Alzheimer's disease

Dosulepin has an established link with a number of adverse cardiovascular effects (hypotension, tachycardia/arrhythmia and QTc prolongation) Relative incidence and severity of side effects is higher than other antidepressants It is extremely toxic in overdose - warn about accidental overdose

Handy chart comparing antidepressant treatments: https://www.choiceandmedication.org/generate.php?s id=55&fname=handychartdepression.pdf

### **Stopping dosulepin** (and not replacing with an alternative antidepressant)

Dosulepin should not be stopped abruptly unless serious side effects have occurred. Slowly tapering the dose in 25 – 50 mg increments over 3 to 4 weeks, or longer if necessary, can help prevent discontinuation symptoms such as anxiety, flu-like symptoms and insomnia. The rate at which the dose is reduced will need to be individualised for each patient, according to the starting dose, how long they have been taking dosulepin and the occurrence of withdrawal symptoms during the reduction. Some people may require a more gradual tapering of the dose over a long period of time to withdraw successfully.

Title	Dosulepin Deprescribing Guidance		
Approved by	Drug & Therapeutics Committee	Date of Approval	22 <sup>nd</sup> July 2021
Protocol Number	PHARM-0059-v3	Date of Review	1 <sup>st</sup> August 2024



### Switching to another antidepressant 5,6

There should be very close monitoring of patients being switched from dosulepin to another antidepressant, as there are no published guidelines to determine exactly how the switch should take place. The switch will need to be tailored to each individual and carried out cautiously. The regimen should depend upon the reason for the switch, how severe the depression is and which drug is being switched to. It is ideal to completely withdraw dosulepin before starting the new drug; however, cross-tapering is usually necessary to maintain symptom control. The dose of dosulepin should be at least halved before starting the new drug. Further reductions in dosulepin dose should occur once the new treatment is established. There is a risk of enhanced side-effects and serotonin syndrome during the overlap phase.

The choice of new antidepressant should be discussed with the patient. Considerations include:

- Depressive (target) symptoms
- Relative side effects of antidepressants (see handy chart, link above)
- Physical co-morbidities
- Interactions with other prescribed medication

Patient profile	Suggested options		
In need of sedation	Mirtazapine (lower doses more sedating)		
In need of activation	SSRI or venlafaxine		
Cardiac disease	Mirtazapine or sertraline		
Diabetes	SSRIs (fluoxetine or sertraline) or venlafaxine		
Epilepsy	SSRIs		
Hepatic impairment	Citalopram (maximum dose 20 mg/day) – see Trust guidance		
Renal impairment	Citalopram		
Parkinson's disease	SSRIs		
Stroke	SSRIs (citalopram if taking warfarin + consider PPI for gastric		
	protection) or mirtazapine		

Very general guidance on switching from dosulepin to other antidepressants is below:

- Dosulepin to an **SSRI**: gradually reduce the dose to 25-50 mg / day, then add SSRI at usual starting dose. Then slowly withdraw the remaining dosulepin over 5-7 days
- Dosulepin to mirtazapine: cross taper cautiously
- Dosulepin to **venlafaxine**: cross taper cautiously starting with venlafaxine 37.5 mg daily

### **Patient Information Leaflets**

Available online at:

- <a href="https://www.prescqipp.info/resources/category/414-items-which-should-not-routinely-be-prescribed-in-primary-care-patient-leaflets">https://www.prescqipp.info/resources/category/414-items-which-should-not-routinely-be-prescribed-in-primary-care-patient-leaflets</a>
- https://www.choiceandmedication.org/generate.php?sid=55&fname=pilldosulepin.pdf

#### References

- 1. Medicines and Healthcare products Regulatory Agency. Drug Safety Update: vol.1, issue 5. December 2007
- 2. NHS England. <u>Items which should not routinely be prescribed in primary care: Guidance for CCGs</u>, Version 2. June 2019
- 3. NICE CG90. Depression in adults: recognition and management. October 2009
- 4. <u>PrescQIPP. DROP-List (Drugs to Review for Optimised Prescribing): Bulletin 126, April 2016</u>
- 5. Bazire S. Psychotropic Drug Directory 2020/21. Lloyd-Reinhold Publications, Norwich.
- 6. Taylor D et al. Maudsley Prescribing Guidelines in Psychiatry, 13th Edition

Title	Dosulepin Deprescribing Guidance		
Approved by	Drug & Therapeutics Committee	Date of Approval	22 <sup>nd</sup> July 2021
Protocol Number	PHARM-0059-v3	Date of Review	1st August 2024